Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results.
Lynch syndrome
The Cancer Genome Atlas
consent
endometrial carcinoma
immunohistochemistry
mismatch repair
screening
terminology
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
17
03
2019
accepted:
22
05
2019
pubmed:
17
7
2019
medline:
28
4
2020
entrez:
17
7
2019
Statut:
ppublish
Résumé
Lynch syndrome (LS) is associated with an increased risk of developing endometrial carcinoma (EC) and ovarian carcinoma (OC). There is considerable variability in current practices and opinions related to screening of newly diagnosed patients with EC/OC for LS. An online survey was undertaken to explore the extent of these differences. An online questionnaire was developed by a panel of experts and sent to all members of the British Association of Gynaecological Pathologists (BAGP) and the International Society of Gynecological Pathologists (ISGyP). Anonymised results were received and analysed. Thirty-six BAGP and 44 ISGyP members completed the survey. More than 90% of respondents were aware of the association of LS with both EC and OC, but 34% were not aware of specific guidelines for LS screening. Seventy-one per cent of respondents agreed that universal screening for LS should be carried out in all newly diagnosed EC cases, with immunohistochemistry (IHC) alone as the preferred approach. Only 36% of respondents currently performed IHC or microsatellite instability testing on all newly diagnosed EC cases, with most of the remaining respondents practising selective screening, based on clinical or pathological features or both. A significant minority of respondents (35%) believed that patient consent was required before performance of mismatch repair (MMR) protein IHC. Almost all respondents favoured the use of standardised terminology for reporting MMR protein staining results, and this is proposed herein. There is wide support for universal LS screening in patients with EC, but this survey highlights areas of considerable variation in practice.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-824Subventions
Organisme : Medical Research Council
ID : MR/M018431/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR-CS-012-009
Pays : United Kingdom
Organisme : Manchester NIHR Biomedical Research Centre
ID : IS-BRC-1215-20007
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 2009; 76; 1-18.
Singh H, Schiesser R, Anand G, Richardson PA, El-Serag HB. Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin. Gastroenterol. Hepatol. 2010; 8; 523-529.
Moller P, Seppala T, Bernstein I et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017; 66; 464-472.
Ryan NAJ, Evans DG, Green K, Crosbie EJ. Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecol. Oncol. 2017; 144; 491-495.
Ryan NAJ, Morris J, Green K et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol. 2017; 3; 1702-1706.
Lu KH, Dinh M, Kohlmann W et al. Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol. 2005; 105; 569-574.
Moller P, Seppala T, Bernstein I et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut 2017; 66; 1657-1664.
Win AK, Lindor NM, Winship I et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J. Natl Cancer Inst. 2013; 105; 274-279.
Moller P, Seppala TT, Bernstein I et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018; 67; 1306-1316.
Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378; 2081-2087.
Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 2006; 354; 261-269.
Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 2018; 143(Suppl. 2); 37-50.
Haraldsdottir S, Hampel H, Tomsic J et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014; 147; 1308-1316.
Djordjevic B, Broaddus RR. Laboratory assays in evaluation of Lynch syndrome in patients with endometrial carcinoma. Surg. Pathol. Clin. 2016; 9; 289-299.
Stelloo E, Jansen AML, Osse EM et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann. Oncol. 2017; 28; 96-102.
Mills AM, Longacre TA. Lynch syndrome screening in the gynecologic tract: current state of the art. Am. J. Surg. Pathol. 2016; 40; e35-e44.
Bartosch C, Clarke B, Bosse T. Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology 2018; 50; 222-237.
NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. 2017. https://www2.tri-kobe.org/nccn/guideline/gynecological/english/uterine.pdf
Colombo N, Creutzberg C, Amant F et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann. Oncol. 2016; 27; 16-41.
Crosbie EJ, Ryan NAJ, Arends MJ et al. The Manchester International Consensus Group Recommendations for the Management of Gynecological Cancers in Lynch Syndrome. Genet. Med. 2019. https://doi.org/10.1038/s41436-019-0489-y [Epub ahead of print].
Cho KR, Cooper K, Croce S et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines from the Special Techniques and Ancillary Studies Group. Int. J. Gynecol. Pathol. 2019; 38(Suppl. 1); S114-S122.
Singh N, Hirschowitz L, Zaino R et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). Int. J. Gynecol. Pathol. 2019; 38(Suppl. 1); S93-S113.
Kalloger SE, Allo G, Mulligan AM et al. Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices. Am. J. Surg. Pathol. 2012; 36; 560-569.
Mascarenhas L, Shanley S, Mitchell G et al. Current mismatch repair deficiency tumor testing practices and capabilities: a survey of Australian pathology providers. Asia Pac. J. Clin. Oncol. 2018; 14; 417-425.
Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015; 372; 2509-2520.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67-73.
Talhouk A, McConechy MK, Leung S et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 2015; 113; 299-310.
Stelloo E, Nout RA, Osse EM et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 2016; 22; 4215-4224.
Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv. Anat. Pathol. 2013; 20; 378-386.
Chui MH, Ryan P, Radigan J et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am. J. Surg. Pathol. 2014; 38; 1173-1181.
Ryan NAJ, Bolton J, McVey RJ, Evans DG, Crosbie EJ. BRCA and Lynch syndrome-associated ovarian cancers behave differently. Gynecol. Oncol. Rep. 2017; 22; 108-109.
Espinosa I, Jose Carnicer M, Catasus L et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am. J. Surg. Pathol. 2010; 34; 1708-1714.
Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014; 146; 643-646.
Mills AM, Sloan EA, Thomas M et al. Clinicopathologic comparison of Lynch syndrome-associated and ‘Lynch-like’ endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry. Am. J. Surg. Pathol. 2016; 40; 155-165.
Malpica A, Euscher ED, Hecht JL et al. Endometrial carcinoma, grossing and processing issues: recommendations of the International Society of Gynecologic Pathologists. Int. J. Gynecol. Pathol. 2019; 38(Suppl. 1); S9-S24.
Downes MR, Allo G, McCluggage WG et al. Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. Histopathology 2014; 65; 228-239.